Experts Discuss IOM Evaluation Of PEPFAR, Implications Of HPTN 052 For U.S. HIV/AIDS Efforts At Panel Discussion

The Center for Global Health Policy’s “Science Speaks” blog reports on a panel discussion held April 30, convened by the Kaiser Family Foundation (KFF) and the Center for Strategic and International Studies’ (CSIS) Global Health Policy Center, which focused on the policy implications of an Institute of Medicine (IOM) evaluation of PEPFAR released in February. Focusing on discussion at the event surrounding the HPTN 052 study, which “unequivocally linked early antiretroviral treatment for HIV with a 96 percent drop in transmitting the virus to an uninfected partner,” the blog notes that while the IOM evaluation acknowledged the study, some panelists thought further discussion of the implications for U.S. HIV/AIDS efforts was needed. The panel, which also addressed the transition of PEPFAR programs to countries, the sustainability of efforts, and the PEPFAR Blueprint: Creating an AIDS-Free Generation (.pdf), included J. Stephen Morrison, vice president and director of the CSIS Global Health Policy Center, who moderated the panel; Jennifer Kates, vice president and director of global health and HIV policy at KFF;  Chris Collins, vice president and director of public policy at amfAR, the Foundation for AIDS Research; Julia Martin, Deputy Global AIDS Coordinator; and Kimberly Scott, senior program officer at the IOM (Barton, 5/3).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.